All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

3 things you should consider when treating frail patients

During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Sonja Zweegman, Amsterdam UMC, Amsterdam, NL. We asked, Which 3 things should you consider when treating frail patients? 

3 things you should consider when treating frail patients

In this video, Zweegman outlines the levels of frailty in patients over 70, and how therapies such as dexamethasone and lenalidomide can be adapted for intermediate–fit and frail patients. She highlights a recent trial that found patients defined as frail based on their age had superior progression-free survival than those defined as frail because of comorbidities.